

Zineb

$$S \xrightarrow{S^{-}} S \xrightarrow{S^{-}} S$$

HN

NH

Molecular Weight: 275.7

CAS Registry No.: 12122-67-7



Listing History: Zineb

- Listed under Proposition 65 on January 1, 1990
- Originally classified by U.S. EPA as a Group B2 carcinogen (U.S. EPA, 1988)
- Entered into, then dropped from Special Review process
- Never re-classified



Reviews by Other Authoritative Bodies

- IARC (1976; 1987)
 - ◆ Group 3 carcinogen
 - insufficient evidence in animals
 - no human data



Carcinogenicity Data Available: Zineb

- Mouse sub-chronic oral studies (Chernov and Khitsenko, 1969)
 - Increased lung adenomas in C57BL mice
- Rat long-term oral studies (Mitsumori et al., 1979)
 - Increased thyroid tumors in rats (primarily cystic adenomas)



Lung Tumors in Mice (Chernov & Khitsenko, 1969)

| C57BL mice | Dose (mg/kg _{bw}) | | | |
|-----------------|-----------------------------|------|-------|--|
| Lung adenomas | 0 | 1750 | 3500 | |
| High-dose study | 0/87 | | 6/79* | |
| Low-dose study | 0/59 | 2/29 | | |

| Strain A mice | Dose (mg/kg _{bw}) | | |
|-----------------|-----------------------------|--|--------|
| Lung adenomas | 0 | | 3500 |
| High-dose study | 30/97 | | 35/101 |

^{*}Significant increase relative to controls (p < 0.05, by Fisher's Exact test)



Thyroid tumors in rats (Mitsumori et al., 1979)

- Rats (80/sex/group) treated with zineb in diet at 0, 40, 200, 1000, 5000 ppm for 130 weeks
- Increased thyroid tumors in males at 5000 ppm
 - ◆ 37.5% treated *vs.* 11.3% controls
 - primarily cystic adenomas
- Increased subcutaneous fibromas in males at 5000 ppm



Non-positive studies: Zineb

- Mouse oral studies (Innes et al., 1969) small; less-than-lifetime
- Mouse s.c. injection studies (NTIS, 1968) - small; less-than-lifetime
- Rat gavage and s.c. implant studies (Andrianova & Alekseev, 1970) - poor survival
- Rat oral studies (Blackwell-Smith et al., 1953) - small study



Other Relevant Data: Zineb

| Species, strain | Endpoint | Results | Reference |
|---------------------------------------------------|-------------------------------------------------------|---------|-------------------------------------------------------------|
| Salmonella typhimurium | Reverse mutation | _ _ | Croce <i>et al.</i> , 1995 Franekic <i>et al.</i> , 1994 |
| Bacillus subtilis | DNA damage Mutation | + + | Shiau <i>et al.</i> , 1980 Felkner <i>et al.</i> , 1981 |
| Saccharomyces cerevisiae | Gene mutation Mitotic chromosome malsegregation | + + | Franckic <i>et al.</i> , 1994 Croce <i>et al.</i> , 1995 |
| Drosophila melanogaster | Genetic damage to somatic and germ cells Mutagenicity | + | Tripathy <i>et al.</i> , 1988 Benes and Sram, 1969 |
| Human peripheral Increased chromosome aberrations | | + | Pilinskaya, 1974 (cited in IARC, 1976) |



Other Relevant Data: Zineb

- Structural similarity to other ethylene bisdithiocarbamate carcinogens (mancozeb, maneb, metiram)
- Metabolized / degraded to ethylene thiourea



Summary: Zineb

- Animal evidence includes benign lung tumors in mice and primarily benign thyroid tumors in rats
- Supporting evidence includes:
 - Some evidence of genotoxicity
 - Structural similarity to known carcinogens
 - Metabolism / degradation to ETU, a known carcinogen, with site concordance